TTK Healthcare to Issue Rs.706.52 Crore Bonus Non-Convertible Redeemable Preference Shares with 9.5% Dividend
Scheme approved for issuance of 5 NCRPS for every equity share, redeemable within 15 months and proposed listing on BSE and NSE
TTK Healthcare Limited's Board approved a Scheme for issuing 7,06,51,665 Non-Convertible Redeemable Preference Shares worth Rs.706.52 crores as bonus to equity shareholders, at a ratio of 5 NCRPS per equity share. The preference shares carry a 9.5% annual dividend and a 15-month tenure with redemption options.
TTK Healthcare Limited
Acquisition / Amalgamation / Merger / Demerger
TTK Healthcare Limited's Board approved a Scheme of Arrangement to issue 7,06,51,665 Non-Convertible Redeemable Preference Shares (NCRPS) as a bonus to its equity shareholders, at a ratio of 5 NCRPS per equity share held as on record date. These NCRPS have a face value of Rs.100 each and carry an annual dividend rate of 9.5% with a redemption tenure of 15 months.
The bonus issue will utilize the company’s reserves or retained earnings to allot NCRPS valued at Rs.706.52 crores. The dividend accrues from allotment date up to March 31 of the financial year, and thereafter on each March 31 until redemption.
Redemption of the NCRPS will be at par after 15 months from allotment or earlier at the Board’s option. The shares are proposed to be listed on both BSE Limited and National Stock Exchange of India Limited.
This issuance follows approvals required from statutory, regulatory authorities, including National Company Law Tribunal (NCLT), stock exchanges, shareholders, and creditors as applicable.
Pre-bonus, TTK Healthcare's total issued equity share capital stands at Rs.14.13 crores (1.41 crore shares of Rs.10 each). Post issuance, the company’s authorised share capital increases to Rs.7,50,00,00,000 including 7.3 crore NCRPS and equity share capital remains unchanged.
The Scheme document will be available on the company’s website after filing with stock exchanges.
Highlights
- Bonus issue ratio: 5 NCRPS of Rs.100 each for every 1 equity share of Rs.10
- Total NCRPS to be issued: 7,06,51,665 shares amounting to Rs.706.52 crores
- Dividend rate fixed at 9.5% per annum, accruing annually with first accrual from allotment date
- Tenure of NCRPS: 15 months with option for earlier redemption by Board
- Proposed listing on BSE and NSE
- Funding through utilization of general reserves and/or retained earnings as per September 30, 2026 figures
Key Data Snapshot
What happened
- TTK Healthcare's Board approved a Scheme for issuance of NCRPS by way of bonus to its equity shareholders.
- The issuance is on a 5:1 ratio of NCRPS per equity share held as on the record date.
- NCRPS carry a 9.5% annual dividend and a 15-month redemption tenure, redeemable earlier at the Board's discretion.
Key details
- Total number of NCRPS issued: 7,06,51,665 amounting to Rs.706.52 crores.
- Dividend accrual from allotment to March 31 of the financial year, thereafter annually.
- NCRPS to be listed on BSE and NSE, the same exchanges where equity shares are listed.
- Funding will use general reserves and/or retained earnings as of September 30, 2026.
- Pre-bonus equity shares total 1,41,30,333 with Rs.14.13 crores paid-up capital.
- Post-bonus authorised share capital increases to Rs.7,50,00,00,000.
Regulatory and governance context
- The Scheme is subject to approvals from National Company Law Tribunal (NCLT), stock exchanges, shareholders, and creditors as required.
- Details of the Scheme will be made available on the company website after stock exchange filing.
- The issuance aligns with SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
- Financial figures related to reserves and earnings are based on limited reviewed results as of September 30, 2026.
Highlights
- Bonus issue ratio: 5 NCRPS of Rs.100 each for every 1 equity share of Rs.10
- Total NCRPS to be issued: 7,06,51,665 shares amounting to Rs.706.52 crores
- Dividend rate fixed at 9.5% per annum, accruing annually with first accrual from allotment date
- Tenure of NCRPS: 15 months with option for earlier redemption by Board
- Proposed listing on BSE and NSE
- Funding through utilization of general reserves and/or retained earnings as per September 30, 2026 figures
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Companies Act, 2013
- SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026
More News on Acquisition / Amalgamation / Merger / Demerger
View allLatest corporate announcements and market updates in Acquisition / Amalgamation / Merger / Demerger.
Raymond Limited Secures NCLT Approval for Merger with Everblue Apparel Limited
Raymond Limited announced that the National Company Law Tribunal, Mumbai bench, approved its Scheme of Amalgamation with Everblue Apparel Limited on November 20, 2026, with the effective date set as April 1, 2026. The merger consolidates the garmenting operations of its wholly owned subsidiary into Raymond Limited without any new shares being issued.
Read Full StoryCESC Limited Revises Renewable Energy Acquisition Completion to December 15, 2026, Boosting Capacity to 1.8 GWp
CESC Limited has extended the completion date of its acquisition of six renewable energy subsidiaries from ReNew Solar Power Private Limited to December 15, 2026, expanding its operational renewable power capacity to approximately 1.4 GW and total portfolio to 4.8 GWp.
Read Full StoryNHPC Limited Gets Central Government Sanction for Amalgamation with Jalpower Corporation Limited
NHPC Limited announced that the Ministry of Corporate Affairs granted sanction for the scheme of amalgamation with its wholly owned subsidiary, Jalpower Corporation Limited. This approval, dated November 17, 2026, allows the merger to proceed upon filing with the Registrar of Companies.
Read Full Story